Intellia has named John Leonard, M.D., President and CEO, effective January 1, 2018. Source: BioSpace

Under terms of the deal, Boehringer has the option to acquire Autifony's Kv3.1/3.2 positive modulator platform, which includes the company's lead compound AUT00206. Source: BioSpace

Now that we've got the bad news out of the way, we’re here to spread some Christmas cheer with the biggest clinical successes in biotech over the past 12 months.…

Dr. Ryan becomes a Director of the Company effective immediately and will assume his responsibilities as CEO effective February 15, 2018. Source: BioSpace

The round was led by Bain Capital Life Sciences. Source: BioSpace

Ultragenyx CEO Emil Kakkis said the sale of the PRV will provide the company with an "important source of non-dilutive capital" that will be used to advance the company's pipeline…

Boehringer's global head of information technology, Michael Schmelmer, will replace Menne on Jan. 1, 2018. Source: BioSpace

Merck's Keytruda came up short in a pivotal Phase III trial as a second-line treatment for patients with advanced gastricadenocarcinoma or GEJ adenocarcinoma. Source: BioSpace

Biotechs are taking notice as a new pool of funding is being made available by venture capital Andreesen Horowitz. Source: BioSpace

Asklepios BioPharma is forming a new biotech portfolio company, Actus Therapeutics. Source: BioSpace